#USA #Los Angeles #TORL BioTherapeutics #Aran Maree #ixotatug vedotin

TORL BioTherapeutics Welcomes New CEO Aran Maree, M.D.

On May 7, 2026, TORL BioTherapeutics LLC (referred to as TORL), a pioneering biotechnology firm specializing in oncology, officially announced a significant leadership shift. Aran Maree, M.D., who has served as the company's Chief Medical Officer since 2024, was appointed as the new Chief Executive Officer and joined the Board of Directors. He succeeds Mark Alles, who will take on the role of Chairman of the Board while continuing to mentor the company's strategic direction.

A Strategic Transition for Growth

This leadership transition is part of a carefully orchestrated plan aimed at positioning TORL for its next growth phase. As Mark Alles stated, the choice of Dr. Maree, with his extensive career and proven leadership skills, is expected to steer TORL through pivotal clinical milestones. Dr. Maree's commitment to enhancing patient outcomes aligns perfectly with the company’s mission of developing cutting-edge cancer therapies.

"TORL was founded to discover, develop, and commercialize first- and best-in-class cancer therapeutics," said Alles. He expressed confidence that Dr. Maree possesses the necessary expertise and passion needed to innovate and guide the company toward its future ambitions.

Dr. Maree's Journey and Contributions

Dr. Maree joined the TORL team back in October 2024. In his former role as Chief Medical Officer, he played a crucial role in the advancement of the first-in-class Claudin 6 (CLDN6)-targeted antibody-drug conjugate (ADC) known as Ixotatug vedotin (Ixo-V; TORL-1-23). Under his leadership, global enrollment in the registration phase 2 study, CATALINA-2, focused on platinum-resistant ovarian cancer (PROC), was significantly accelerated. Furthermore, he has initiated the development of several Investigational New Drug (IND) applications, including a hematology asset that has already progressed into Phase 1 trials.

In his acceptance speech as CEO, Dr. Maree shared his enthusiasm about leading TORL forward, emphasizing a commitment to advancing Ixo-V toward its regulatory filings and expanding the company’s early-stage pipeline. His dedication to developing therapies that can genuinely uplift the lives of cancer patients reiterates TORL's vision.

Strengthening Leadership for Future Growth

The appointment of Dr. Maree is not an isolated development; it reflects TORL’s broader strategic initiative designed to bolster its leadership team and governance to successfully navigate late-stage development and potential commercialization. With a focus on preparing for future growth, TORL has also recently appointed several accomplished leaders in key positions. These include:

• - Christine Loggins, MBA - Chief Operating Officer
• - Steve Ritland, Ph.D. - Chief Scientific Officer
• - Vince Ruiz, J.D. - General Counsel

Together, this experienced team brings with them decades of experience in building biotechnology companies and creating transformative therapies for patients with substantial unmet medical needs.

TORL's Promising Pipeline and Future Aspirations

To date, TORL has successfully raised over $450 million from top-tier biotechnology investors, surging ahead with its ambitious clinical pipeline. In addition to its lead CLDN6 program, the company’s research portfolio includes another ADC aimed at targeting Delta-like Non-canonical Notch Ligand 1 (DLK1) and other undisclosed targets across solid tumors and hematological cancers.

Understanding Claudin 6: This protein is predominantly expressed in various cancers while being virtually absent in normal tissues, rendering it an ideal target for ADC development. Elevated levels of CLDN6 are linked with adverse outcomes in several malignancies including ovarian and endometrial cancers.

About Ixotatug Vedotin (Ixo-V; TORL-1-23): As a first-in-class clinical-stage ADC, Ixo-V is poised to tackle CLDN6-positive solid tumors and has received Fast Track Designation from the U.S. FDA.

The CATALINA-2 study, which focuses on women with CLDN6-positive PROC, represents a key effort in TORL's clinical strategy, assessing critical endpoints such as objective response rate and overall survival.

Conclusion

With Aran Maree at the helm, TORL BioTherapeutics is set to navigate its next chapter. The company's unwavering dedication to addressing complex oncology challenges sets the stage for a promising future in the biopharmaceutical landscape. As they move forward under new leadership, the potential for growth and innovation in cancer treatment looks brighter than ever.